The Role of Government and Private Insurers in Guiding and Implementing Pharmacoeconomic Analyses Deborah A. FreundBryan R. Luce Current Opinion 18 October 2012 Pages: 383 - 387
The (Near) Equivalence of Cost—Effectiveness and Cost-Benefit Analyses Cam Donaldson Current Opinion 18 October 2012 Pages: 389 - 396
An Introduction to Markov Modelling for Economic Evaluation Andrew BriggsMark Sculpher Leading Article 18 October 2012 Pages: 397 - 409
The Use of QALY and Non—QALY Measures of Health—Related Quality of Life Mark DeverillJohn BrazierAndrew Booth Review Article 18 October 2012 Pages: 411 - 420
Valuation of EuroQOL (EQ-5D) Health States in an Adult US Sample Jeffrey A. JohnsonStephen Joel CoonsGeorge Szava-Kovats Original Research Article 18 October 2012 Pages: 421 - 433
Antidepressant Selection and Use and Healthcare Expenditures William H. CrownTimothy R. HylanLaurie Meneades Original Research Article 18 October 2012 Pages: 435 - 448
Evaluation of the Potential Clinical and Economic Effects of Bodyweight Stabilisation with Acarbose in Patients with Type 2 Diabetes Mellitus Kurt BanzRolf DinkelUta Schwanebeck Original Research Article 18 October 2012 Pages: 449 - 459
Pharmacoeconomic Analysis of 3 Treatment Strategies for Cytomegalovirus Retinitis in Patients with AIDS Robert I. GriffithsGiselle C. BleeckerEarl P. Steinberg Original Research Article 18 October 2012 Pages: 461 - 474